Kenneth A Richardson

US Patent:

6359007, Mar 19, 2002

Filed:

Mar 23, 2000

Appl. No.:

09/534909

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

ChronoRX, LLC - Anchorage AK

International Classification:

A61K 31195

US Classification:

514565

Abstract:

Various clinical uses for L-arginine complexes are presented. The active agents have individual and complementary physiological functions especially as these relate to conditions and functions, which influence endothelial biochemistry and physiology. The active components of the invention are selected for inclusion in unique combinations that will clinically reduce risks of vasculopathy in various diseases. The reduction of endothelial dysfunctional risks, often associated with aging and generalized poor vascular health and function, will maximize the potential clinical therapeutic success of other mediations and concurrently avoid some risks of pharmaceutical side effects.

US Patent:

6423847, Jul 23, 2002

Filed:

Mar 20, 2000

Appl. No.:

09/532658

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC - Anchorage AK

International Classification:

C07D40500

US Classification:

5462827, 514337

Abstract:

A process of synthesis of D,-tocopherol nicotinate compounds is presented. Therapeutic uses for this compound are described. The active agents are demonstrated to be complementary in their physiological functions especially as these relate to cellular and endothelial biochemistry and physiology and, ultimately to vascular health. The active components of the invention are selected for inclusion in a unique combination that clinically reduces risks of vasculopathy, DNA strand breakage and neuronal excitotoxicity in various diseases. In addition to the systemic vascular benefits acquired, improvement of the vascular health of the eye reduces the risk of glaucomatous optic nerve atrophy with its accompanying visual field loss and potential blindness and reduces conditions of risk for macular degeneration.

US Patent:

6429219, Aug 6, 2002

Filed:

May 3, 2000

Appl. No.:

09/564070

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC - Anchorage AK

International Classification:

A61K 31425

US Classification:

514369, 514494, 514499, 514578

Abstract:

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

US Patent:

6455061, Sep 24, 2002

Filed:

Apr 5, 2001

Appl. No.:

09/828323

Inventors:

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

Assignee:

ChronoRX, LLC - Anchorage AK

International Classification:

A61F 1300

US Classification:

424422, 424427, 424428, 514547, 514574

Abstract:

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D--tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

US Patent:

6524619, Feb 25, 2003

Filed:

Jan 19, 2001

Appl. No.:

09/765974

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, Inc. - Anchorage AK

International Classification:

A61K 920

US Classification:

424472, 424464, 424468

Abstract:

The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIII nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIII nerve atrophy, and the hearing loss and possible deafness that accompany them.

US Patent:

6531608, Mar 11, 2003

Filed:

Jun 11, 2002

Appl. No.:

10/167630

Inventors:

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Assignee:

Chronorx, LLC. - Anchorage AK

International Classification:

C07D27702

US Classification:

548182, 556 45, 556110, 556118, 562557

Abstract:

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

US Patent:

6632445, Oct 14, 2003

Filed:

Jul 30, 2002

Appl. No.:

10/209432

Inventors:

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

Assignee:

ChronoRX, LLC - Anchorage AK

International Classification:

A61E 1300

US Classification:

424422, 424 7804, 4242041, 4242291, 4242311, 424427

Abstract:

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D--tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

US Patent:

6689385, Feb 10, 2004

Filed:

Nov 2, 2001

Appl. No.:

10/033730

Inventors:

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

Assignee:

Chronorx LLC - Anchorage AK

International Classification:

A61K 920

US Classification:

424464, 451472, 451482, 451486, 451489

Abstract:

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.